10.02.2016 • NewsElaine Burridgecancer drugsAstraZeneca

AstraZeneca Cancer Drug Breakthrough

The combination of two cancer drugs from UK-Swedish drugs maker AstraZeneca and its biologics research and development arm MedImmune could be a potential breakthrough in treating a form of lung cancer.

The companies have released results of their Phase IB study where durvalumab and tremelimumab were used to treat patients with progammed death-ligand 1 (PD-L1) negative tumors.

PD-L1 is a protein that is suspected of playing a major in suppressing the immune system. According to AstraZeneca, around two-thirds of patients with non-small cell lung cancer have PD-L1 negative tumors which respond less favorably to treatment than patients with PD-L1 positive tumors.

Initial results from the research were presented at the annual meeting of the Society for Immunotherapy in Cancer last November. The latest publication includes a more detailed analysis of the technique, with a longer follow-up period and more mature data set of confirmed responses.

Scott Antonia, chair of the Department of Thoracic Oncology at Moffitt Cancer Center in Florida, US, said the results suggest that the combination has potential as a treatment for patients with PD-L1 negative tumors whose needs are not addressed by currently available therapies, including immunotherapies.

Describing the new data as an important milestone, Ed Bradley, MedImmune’s senior vice president, oncology, added that the latest findings reinforced the belief that the combination strategy being pursued was key to the future success of immune-oncology treatment.

Durvalumab is an investigational human monoclonal antibody directed against PD-L1, while tremelimumab is a fully human anti-CTLA-4 antibody. Tremelimumab was granted orphan drug status by the US Food and Drug Administration in 2015.

Lung cancer is the leading cause of cancer-related death in both men and women and has a five-year survival rate of less than 20%.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.